Resumen de Continuation of immunotherapy beyond progression is benefcial to the survival of advanced non‑small‑cell lung cancer
Siqi Song, Xiaobo Ding, Chuchu Lin, Bin Wang, Wenfeng Li, Yuanyuan Cheng, Chunhong Zhang, Zhe Ye, Yanru Xie, Xuedan Du
Purpose To investigate the potential clinical importance of continuing immunotherapy beyond progression in patients with advanced non-small-cell lung cancer (aNSCLC).
Methods The data of patients with aNSCLC who experienced progressive disease after receiving frst-line immunotherapy plus chemotherapy were collected from multiple centers for the period from January 1, 2018 to May 31, 2022. According to the second-line treatment, the patients were classifed into two groups: the continuation of immunotherapy beyond progression (CIBP) group and the discontinuation of immunotherapy beyond progression (DIBP) group. The efcacy and safety of the treatment were compared between the groups.
Results Overall, data from 169 patients were analyzed; 93 patients were enrolled in the CIBP group and 76 patients were in the DIBP group. The median second-line progression-free survival was 5.5 months in the CIBP group, which for the DIBP group was 3.4 (p=0.011). The median overall survival of the CIBP group was 13.3 months, whereas that of the DIBP group was 8.8 months (p=0.031). The disease control rate of the CIBP group (79.57%) was observably higher than that of the DIBP group (64.47%; p=0.028). Among patients who responded better (complete or partial response) to prior therapy, the median progression-free survival was 5.5 months and 3.3 months in the CIBP and DIBP groups respectively (p=0.022), and the median overall survival was 14.8 months and 8.8 months in the CIBP and DIBP groups respectively (p=0.046).
Conclusions Continuing immunotherapy as a second-line treatment could be benefcial to the survival of patients with aNSCLC with disease progression beyond initial chemotherapy combined with immunotherapy.
